Flash FinanceUS
Pre-market S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Bionano Genomics, Inc. (BNGO)

Bionano Genomics Q2 2026 revenue of $8.2M beats guidance; FY26 low end raised

Positive Impact 3 of 5 earnings Written later

In a Regulation FD filing tied to the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026, Bionano presented Q2 2026 results showing revenue of $8.2 million, above its $7.5 million to $7.8 million guidance and up 21% from Q2 2025. The company raised the lower end of its FY26 revenue guidance to $31 million to $33 million from $30 million to $33 million, and it projects FY27 revenue of $50 million to $54 million. The filing also repeats that the company's ability to continue as a going concern depends on obtaining significant additional financing.

Key points

  • Q2 2026 revenue was $8.2 million, above guidance of $7.5 million to $7.8 million and up 21% from Q2 2025.
  • FY26 revenue guidance is $31 million to $33 million, with the lower end raised from $30 million.
  • FY27 revenue outlook is $50 million to $54 million, with adjusted EBITDA projected at about $0 in the Q4 FY27 exit rate.
  • The company disclosed that its ability to continue as a going concern requires significant additional financing.

The filing

CompanyBionano Genomics, Inc. (BNGO)
Form8-K, current report
Filed with the SECSep 14, 2026, 8:30 AM ET
Accession number0001411690-26-000046

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 14, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.